Medical technology company Epiminder has announced that its Minder device has recorded continuous Continuous Electroencephalogram (EEG) Monitoring for five years in a study participant.
Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.
Epilepsy affects 80 million people globally, with current medications effective in two in three cases. More than 250,000 Australians and 3.4 million Americans are currently living with epilepsy, the most common brain disorder worldwide that can affect people at any age. Refractory epilepsy affects 30 to 40 per cent of these patients, who cannot be adequately managed by drug therapy to remain seizure-free.
Epiminder said the 5-year milestone is essential in the evolving paradigm of EEG monitoring for drug-resistant epilepsy patients and could open a path to seizure freedom.
CEO Rohan Hoare said, “Our investment in developing the Minder device is proving to clinicians in the field of neurology that long-term, continuous EEG monitoring is becoming a reality. Patients with drug-resistant epilepsy manage a very challenging path to seizure freedom and this is often the result of not having objective long term seizure data for them and their treating neurologist to make the best informed clinical decisions. The Minder continuous EEG monitor holds the promise of delivering actionable insights to clinicians and patients to help them improve seizure control and, for some, achieve seizure freedom.”